Bowman and Brooke Logo

VERDICTS & CASE STUDIES

In early 2018, Law360 named Bowman and Brooke a “2017 Product Liability Group of the Year,” marking the eighth time the firm has received this distinction in the past nine years.

Defending Osteoporosis Prevention Drug

CASE RESULTS DEPEND UPON A VARIETY OF FACTORS UNIQUE TO EACH CASE. CASE RESULTS DO NOT GUARANTEE OR PREDICT A SIMILAR RESULT IN ANY FUTURE CASE.
Heart monitor and pill icon - drug and medical device

 

Bowman and Brooke is National Coordinating, Trial and Discovery Counsel, responsible for global defense strategy for a multi-national pharmaceutical firm defending claims against a drug used to prevent and treat osteoporosis in women. Currently, there are 250 cases filed, with an additional 200 claims. We are scheduled to try the first case in Fall 2013 in the U.S.D.C. New York, Eastern District.